SEC Form 4 · accession 0001638599-16-000695
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William J. Regan
Officer — SVP-Global Regulatory Strategy
Period of report
Dec 17, 2014
Accepted (ET)
Feb 29, 2016 · 5:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.50 | Dec 17, 2014 | A | 25,000 | A | — | Dec 17, 2024 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Option vests as to 6,250 shares upon grant, with balance vesting at the rate of 6,250 shares on January 28 in each of 2016, 2017 and 2018.